Raymond James upgraded shares of Oncolytics Biotech (TSE:ONC - Free Report) to a moderate buy rating in a report issued on Thursday,Zacks.com reports. Raymond James also issued estimates for Oncolytics Biotech's Q4 2024 earnings at ($0.12) EPS, FY2024 earnings at ($0.44) EPS, Q1 2025 earnings at ($0.12) EPS and FY2025 earnings at ($0.47) EPS.
Oncolytics Biotech Stock Down 2.1 %
Shares of Oncolytics Biotech stock traded down C$0.03 during trading on Thursday, hitting C$1.38. The company's stock had a trading volume of 95,200 shares, compared to its average volume of 71,027. The company has a debt-to-equity ratio of 6.09, a quick ratio of 8.86 and a current ratio of 4.99. The company has a fifty day simple moving average of C$1.50 and a two-hundred day simple moving average of C$1.45. The company has a market capitalization of C$106.07 million, a PE ratio of -3.63 and a beta of 1.35. Oncolytics Biotech has a 52 week low of C$1.15 and a 52 week high of C$2.32.
Oncolytics Biotech Company Profile
(
Get Free Report)
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.
See Also
Before you consider Oncolytics Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oncolytics Biotech wasn't on the list.
While Oncolytics Biotech currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
